2026 Hemp Ban: The Industry Is Gambling on Reversal – Preparing for Reality

Eight months from now, the CBD product pet parents are using for their companion animal's arthritis, anxiety, inflammation or seizures might become illegal—not because it's dangerous, not because it doesn't work, but because of a chemical threshold so restrictive that it will eliminate 95% of products currently on the market.

On November 12, 2026, the most significant change to the US federal hemp policy since 2018 takes effect. Public Law 119-37, buried within a government funding bill signed in November 2025, redefines hemp in ways that will reshape the entire CBD industry. The new law replaces the delta-9 THC standard with a "total THC" limit so strict that most full-spectrum CBD products—including the majority of pet CBD—will be classified as marijuana and subject to criminal penalties for possession and sale.

The hemp industry insists this is a "winnable fight." They're lobbying Congress, presenting to the FDA, building coalitions, and investing millions in advocacy. They point to bipartisan support for alternative legislation, economic arguments about jobs and tax revenue, and political winds they believe will shift in time to prevent the ban from taking effect. They've been saying this for months. And they've lost every single battle.

November 2025: the ban was signed into law. January 2026: delay legislation failed. February 2026: the FDA missed its guidance deadline. March 2026: the Farm Bill passed without relief and actually made restrictions stricter. The industry's track record stands at zero wins and four losses, with eight months remaining until the deadline.

Here's the long and short of the 2026 hemp ban: how we got here, what changes on November 12, why the industry keeps losing despite confident predictions, what pet owners need to know, and why choosing transparency and proactive reformulation over political gambling is realistically the only path forward in the new legal framwork.

The Timeline: How We Got Here (And Why the Industry Keeps Losing)

Understanding this timeline is critical for pet owners who rely on CBD for their dogs' health. The hemp industry has fought hard—and lost every single battle. What began as a regulatory loophole in 2018 has become an eight-year saga of explosive growth, regulatory neglect, and now, an industry-wide reckoning that will reshape the entire CBD marketplace by the end of this year.

2018: The Farm Bill "Loophole"

The Agriculture Improvement Act of 2018 removed hemp from the Controlled Substances Act, defining it as cannabis with no more than 0.3% delta-9 THC by dry weight. According to the Congressional Research Service, the law's language—which included "all derivatives, extracts, cannabinoids, and isomers"—unintentionally created what experts now call the "hemp loophole." This seemingly technical definition made lawful certain psychoactive cannabinoids as long as they were derived from hemp, regardless of their intoxicating effects. The result was nothing short of remarkable: a $28.4 billion industry supporting an estimated 300,000 jobs emerged in less than seven years.

2018-2025: Explosive Growth, FDA Inaction

While the hemp industry boomed, the Food and Drug Administration never created a regulatory pathway for CBD products. The agency found itself in an impossible position: hemp was legal under agricultural law, but CBD remained in regulatory limbo under the Federal Food, Drug, and Cosmetic Act. At a 2023 congressional hearing, industry representatives testified that the FDA's inaction had "cast a shadow" over legitimate businesses while allowing unregulated products to flourish without consistent safety standards. For eight years, this standoff continued, with neither side willing to blink first.

November 12, 2025: The Ban Is Signed

President Trump signed the Continuing Appropriations and Extensions Act, 2026 (Public Law 119-37)Public Law 119-37), ending the longest government shutdown in U.S. history. Buried within the legislation was Section 781, a provision that fundamentally redefined hemp. The new definition replaced the delta-9 THC threshold with a "total THC" standard that included THCA, delta-8 THC, and all other THC-class cannabinoids. It capped finished hemp products at just 0.4 milligrams of total THC per container. It banned cannabinoids synthesized outside the plant or not naturally occurring. And it set an effective date of November 12, 2026—exactly one year away.

Legal experts immediately recognized the implications. The 0.4-milligram limit was so restrictive that an estimated 90% or more of "full-spectrum" CBD products—including most pet CBD—would fall outside the amended definition. The industry's response was swift and confident: "We'll fight this. It's not over."

January 2026: No Delay in Spending Bill

The hemp industry mounted its first serious counteroffensive in January 2026. Representative Jim Baird of Indiana introduced the Hemp Planting Predictability Act, a bipartisan bill that would delay implementation by two years to November 2028. The proposal gained traction among lawmakers from agricultural states, and industry advocates believed they had found a viable path forward. But when the January spending bill passed, the delay provision was nowhere to be found. Despite the advocacy, despite the bipartisan support, despite the economic arguments, Congress declined to intervene.

February 10, 2026: FDA Misses Critical Deadline

The November 2025 law had required the FDA to publish, within 90 days, comprehensive lists of naturally occurring cannabinoids, THC-class cannabinoids, and a definition of "container" as it relates to the 0.4-milligram limit. The February 10, 2026 deadline came and went with no publication. As Marijuana Moment reported, Jonathan Miller, general counsel of the U.S. Hemp Roundtable, expressed frustration but not surprise: "The FDA has been quite slow in meeting congressional deadlines when it comes to hemp in the past, and in some cases ignoring congressional deadlines."

The FDA's silence created a cascading crisis. Without official guidance on which cannabinoids count toward the total THC limit, and without a clear definition of "container," businesses couldn't determine which products would be compliant.

March 5, 2026: Farm Bill Passes Without Relief

The House Agriculture Committee voted 34-17 to approve the Farm, Food, and National Security Act of 2026. Representative Baird had filed an amendment to delay the hemp ban, but he was absent from the markup hearing following the death of his wife of 59 years. Committee Chairman Glenn "GT" Thompson of Pennsylvania made the committee's position crystal clear during the proceedings: "The ag appropriations bill that passed last fall brought clarity to the industry on what is or is not allowable under the definitions of hemp. Importantly, to many in this room today, that language addressed the issue of final form products that have been the source of many public health concerns since the 2018 Farm Bill."

Thompson's statement revealed the fundamental problem facing hemp advocates: a jurisdictional turf war. The Agriculture Committee claimed authority over hemp plants but not finished products. The Energy and Commerce Committee, which would have jurisdiction over finished hemp products, hadn't acted. The result was legislative paralysis.

The Farm Bill didn't just fail to provide relief—it actually made things stricter. The legislation imposed a five-year license revocation for farmers who "knowingly produce" cannabinoid hemp while claiming "industrial only" designation.

Meanwhile: A Billionaire Bets $68 Million

As the industry lost battle after battle, Ben Kovler, the 46-year-old CEO and founder of Green Thumb Industries, was making a very different calculation. Kovler runs a $1.1 billion cannabis company with 105 dispensaries across 14 states, and in 2024, he decided to go all-in on hemp-derived THC beverages. Through Rythm Inc., a publicly traded company in which GTI holds a controlling stake, Kovler invested $18.2 million for a 49.99% ownership position, then poured in an additional $50 million via private placement and convertible notes. Total investment: more than $68 million.

In February 2026, as reported by Forbes, Kovler announced that Chicago's United Center would begin selling hemp-derived THC beverages—the first venue of its size in the country to do so. His confidence was striking given the legislative losses piling up around him. But even Kovler, with his billions and his political connections, acknowledged the fundamental risk. When pressed, he admitted: "If the hemp loophole closes, current hemp products would no longer be legal, so we would not be selling products that are illegal." Translation: if the ban stands, his $68 million bet "will go up in smoke."

While Kovler doubled down, other major players were making different calculations. Curaleaf, a Connecticut-based cannabis giant with operations across multiple states, announced it was shuttering its hemp business ahead of the ban. The company's leadership had apparently concluded that the risk of being caught with non-compliant inventory after November outweighed any potential upside from continued operations. Smaller brands began quietly discontinuing products. Retailers started reducing inventory to avoid being stuck with illegal merchandise. The exodus had begun, even as industry advocates continued to insist that victory was within reach.

Despite this track record, industry leaders have maintained a remarkably consistent message. As reported by NACS Magazine, Justin Journay, founder of 3CHI (one of the largest hemp-derived THC manufacturers), told retailers in early 2026: "Now is the time to fight, not after the rules are written without your input. It's a winnable fight, but it requires you to get involved right now."

The New Law Explained: What Changes on November 12, 2026

Public Law 119-37, Section 781, represents the most significant change to federal hemp policy since 2018. The legislation runs more than 800 pages, but the hemp provisions occupy just a few critical paragraphs that will reshape an entire industry.

From Delta-9 to "Total THC"

The 2018 Farm Bill limited hemp to 0.3% delta-9 THC by dry weight. Delta-9 THC is the primary psychoactive compound in cannabis, the one that produces the "high" associated with marijuana. By limiting hemp to 0.3% delta-9, Congress believed it was drawing a clear line between non-intoxicating hemp and intoxicating marijuana. But the cannabis plant is far more complex than that simple distinction suggests.

The new law changes the standard from delta-9 THC alone to "total THC," a term that encompasses delta-9 THC, THCA (tetrahydrocannabinolic acid, which converts to delta-9 when heated), delta-8 THC (a less potent but still psychoactive isomer), and any other THC-class cannabinoids that the FDA eventually identifies in its still-unpublished guidance. Many full-spectrum CBD products contain THCA and trace amounts of various THC isomers that, when combined, exceed the new threshold even though they were perfectly legal under the old standard.

The 0.4 Milligram "De Facto Ban"

The law doesn't stop at redefining the percentage threshold for raw hemp. It goes further, imposing an absolute limit on finished products: no more than 0.4 milligrams of total THC per container. Industry advocates have taken to calling this a "de facto ban," and the math supports their characterization. Most full-spectrum CBD tinctures contain somewhere between two and ten milligrams of total THC per bottle—five to twenty-five times the new legal limit.

The U.S. Hemp Roundtable estimates that 95% of current products would be non-compliant under this standard. As NPR reported in their investigation of Sweetwater Hemp Company in Nebraska, the chief extraction officer stated the impact bluntly: "The federal hemp bill would basically eliminate full-spectrum products."

Ban on Synthetic and Semi-Synthetic Cannabinoids

The law also explicitly excludes cannabinoids that are synthesized or manufactured outside the cannabis plant, as well as cannabinoids that aren't capable of being naturally produced by the plant. This provision targets the semi-synthetic cannabinoid market that exploded after 2018, particularly delta-8 THC. While delta-8 does occur naturally in cannabis, it's present in such tiny amounts that commercial delta-8 products are typically created through chemical isomerization of CBD. The new law treats these semi-synthetic compounds as illegal, regardless of whether they're derived from legal hemp.

The "Container" Definition Crisis

Perhaps the most frustrating aspect of the new law is what it doesn't clarify. The legislation defines "container" as "the innermost wrapping, packaging, or vessel in direct contact with a final hemp-derived cannabinoid product in which the final hemp-derived cannabinoid product is enclosed for retail sale to consumers, such as a jar, bottle, bag, box, packet, can, carton, or cartridge." That sounds specific, but it leaves critical questions unanswered.

Consider a package of CBD gummies. Is the "container" each individual gummy wrapper, or is it the bag that holds all the gummies? The same question applies to tincture bottles with droppers, multi-packs of beverages, and countless other product formats. The FDA was supposed to provide "additional information and specificity" about this term by February 10, 2026. That deadline passed with no publication, no explanation, and no indication of when the guidance might appear.

November 12, 2026: The Deadline

The law provides a 365-day implementation period from the date of enactment. After November 12, 2026, any product that doesn't meet the new definition of hemp will be classified as marijuana under the Controlled Substances Act. That classification carries serious consequences: civil penalties, criminal liability, seizure of inventory, and potential prosecution. The law makes no distinction between someone selling intoxicating delta-8 gummies at a gas station and someone selling non-intoxicating full-spectrum CBD for their dog's arthritis.

Importantly, legal experts note there is no guaranteed "sell-through" safe harbor in the legislation. Some businesses have assumed they can continue selling existing inventory until it's gone, as long as they stop producing new non-compliant products. But the law doesn't explicitly provide for this, and legal analysis from firms like Frier Levitt warns that any non-compliant inventory remaining in commerce after the effective date may be treated as illegal marijuana.

What This Means for Pet Owners: Why Your Dog's CBD Is at Risk

If you're using CBD to manage your dog's arthritis, anxiety, or seizures, the 2026 hemp ban isn't an abstract policy debate—it's a direct threat to your dog's quality of life. The law doesn't distinguish between intoxicating products sold at gas stations and therapeutic pet CBD recommended by veterinarians. It simply draws a line based on total THC content, and most pet CBD products fall on the wrong side of that line.

The Pet CBD Market Is Built on Full-Spectrum Formulations

Walk into any pet store or browse online retailers, and you'll find that the overwhelming majority of CBD products for dogs are marketed as "full-spectrum." This isn't an accident or a marketing gimmick—it reflects a genuine belief among manufacturers and pet owners that full-spectrum products work better than isolated CBD. The theory, known as the "entourage effect," suggests that cannabinoids work synergistically when kept together in their natural ratios.

Most "Non-Intoxicating" CBD Will Be Illegal

This is the part that catches most pet owners by surprise: the ban isn't just targeting products that get people or animals high. It's eliminating products based on a chemical threshold that has nothing to do with psychoactive effects. A typical full-spectrum CBD tincture for dogs might contain 500 milligrams of CBD per bottle and five milligrams of total THC—a ratio of 100 to 1. That tiny amount of THC produces no intoxicating effect in dogs, but it's more than ten times the legal limit under the new law.

As Jonathan Miller of the U.S. Hemp Roundtable told NPR, "That would encompass 95% of the hemp extract industry. Even the vast majority of nonintoxicating CBD products have more than 0.4 milligrams of THC per container."

The Three Risks Pet Owners Face

The first risk is availability. If most current products become illegal in November, and if manufacturers haven't successfully reformulated by then, your dog's CBD might simply disappear from the market. Some companies will exit the market entirely rather than risk the compliance costs and legal liability. Others will attempt last-minute reformulation and produce inferior products in their rush to meet the deadline.

The second risk is quality. When companies scramble to reformulate under time pressure, quality often suffers. Removing THC from a full-spectrum extract isn't as simple as running the product through a filter. It requires new extraction processes or post-processing techniques that companies may not have perfected. Early batches might have inconsistent cannabinoid profiles, contamination issues, or efficacy problems.

The third risk is legal. While it's unlikely that individual pet owners will face prosecution for possessing non-compliant CBD after November, the legal status of these products matters. Retailers may refuse to sell them. Online platforms may delist them. Credit card processors may decline transactions. Veterinarians who currently recommend CBD may become reluctant to do so if the products occupy a legal gray zone.

The Full-Spectrum Reality: Why Most Pet CBD Will Be Affected

Most pet owners don't realize that their "non-intoxicating" CBD product will likely be affected by the new law. The confusion is understandable—the marketing has always emphasized safety, natural ingredients, and therapeutic benefits, never intoxication. But the law doesn't care about marketing claims or intended use. It cares about chemistry.

What "Full-Spectrum" Really Means

The pet CBD market is dominated by products marketed as "full-spectrum," a term that sounds wholesome and natural but has specific chemical implications. Full-spectrum means the product contains all the naturally occurring compounds from the hemp plant: CBD, CBG, CBN, trace amounts of THC in its various forms, and the full complement of terpenes and flavonoids.

The theory behind full-spectrum products is the "entourage effect"—the idea that cannabinoids work better together than in isolation. Proponents argue that CBD extracted and purified into an isolate, stripped of all other compounds, loses some of its therapeutic potential. Regardless of whether the entourage effect is real or overstated, it's been the guiding philosophy behind product development for nearly a decade.

The Problem: "Trace Amounts" Add Up

Here's where the chemistry becomes a legal problem. Most full-spectrum pet CBD products contain what the industry calls "trace amounts" of THC. In a typical 30-milliliter bottle of CBD tincture, you might find 500 milligrams of CBD and somewhere between two and ten milligrams of total THC. That's a ratio of roughly 50 to 1 or even 100 to 1—far too little THC to produce any psychoactive effects in dogs.

But under the new law's 0.4-milligram per container limit, these products are non-compliant by a factor of five to twenty-five. A product with five milligrams of total THC per bottle exceeds the legal limit by more than twelve times. It doesn't matter that the product is non-intoxicating. It doesn't matter that it's been legal for eight years. The chemistry puts it on the wrong side of the line.

Why Companies Face Three Hard Choices

Every company in the hemp-derived CBD industry is facing the same fundamental question: what do we do between now and November 12, 2026? The answer isn't obvious, and each option carries significant risks and costs.

Option One: Reformulate to Remove All THC

The most straightforward path to compliance is reformulation—creating new products that meet the 0.4-milligram total THC limit or, more safely, achieving true 0.0% THC to eliminate any ambiguity about compliance. This sounds simple in theory but proves extraordinarily complex in practice. Removing THC from a full-spectrum extract isn't like filtering out sediment from water. THC molecules are chemically similar to other cannabinoids, particularly CBD, which makes selective removal challenging. The most common approach involves chromatography, a process that separates compounds based on their molecular properties, but it requires specialized equipment, technical expertise, and significant capital investment.

Companies that choose this path face a timeline problem. Developing a new extraction process or adding post-processing steps takes months of research and development. You need to test different methods, optimize parameters, verify that you're actually removing all the THC without degrading other beneficial compounds, and then validate the process across multiple batches to ensure consistency. The entire process, done properly, takes six to twelve months—and we're already eight months from the deadline.

There's also the efficacy question. Will a product with 0.0% THC work as well as the full-spectrum formulation that customers have been using? Proponents of the entourage effect argue that removing THC diminishes therapeutic benefits, though the scientific evidence for this claim remains debated. What's certain is that customers will notice the change, and if the reformulated product doesn't work as well—or if they simply perceive it as less effective—they may switch to competitors or abandon CBD entirely.

The financial costs are substantial. New equipment, new processes, new testing protocols, new labeling, new marketing materials explaining the change—it all adds up quickly. Smaller companies may lack the capital to invest in reformulation, forcing them toward one of the other options.

Option Two: Exit the Market

The second option is to simply exit the hemp-derived CBD market entirely. For some companies, this is the rational economic choice. If reformulation costs exceed the expected future profits from CBD sales, if the regulatory uncertainty makes long-term planning impossible, if the company has other product lines that can absorb the revenue loss, then exiting may make more sense than fighting to stay compliant. This is exactly what Curaleaf decided to do, announcing it was shuttering its hemp business ahead of the ban.

Curaleaf isn't alone. Smaller brands are quietly discontinuing products without public announcements, simply letting inventory run out and not placing new orders with manufacturers. Retailers are reducing their hemp CBD sections, unwilling to commit shelf space to products that might become illegal in a few months. The exodus is happening gradually, almost invisibly, but it's real and it's accelerating as November approaches.

For companies with diversified product lines, exiting hemp CBD might be a minor adjustment. But for companies built entirely around hemp-derived products, exit means shutting down the business. It means laying off employees, terminating supplier contracts, liquidating inventory, and walking away from years of investment in brand building and customer relationships.

Option Three: Gamble on Legislative Reversal

The third option is to do nothing and hope that the ban is reversed, delayed, or modified before November. This is the path that much of the industry has chosen, either explicitly or through inaction. The logic is straightforward: why invest millions in reformulation if there's a chance the law will change? Why exit a profitable market if Congress might pass delay legislation?

This gamble is based on several assumptions. First, that the economic impact of the ban—$28.4 billion in revenue, 300,000 jobs, $1.5 billion in state tax revenue—will eventually force Congress to act. Second, that the bipartisan support for alternative legislation like the HEMP Act or delay bills will translate into actual votes. Third, that the alcohol industry's shift from supporting the ban to lobbying for delay will create enough political pressure to change outcomes. Fourth, that the FDA's failure to provide required guidance will be seen as grounds for extending the implementation timeline.

These aren't unreasonable assumptions. The economic arguments are real. The bipartisan support exists. The alcohol lobby has indeed switched sides. The FDA did miss its deadline. But assumptions aren't results, and the industry has lost every legislative battle so far. They assumed the ban wouldn't pass—it did. They assumed delay legislation would be included in the January spending bill—it wasn't. They assumed the FDA would provide guidance—it didn't. They assumed the Farm Bill would offer relief—it made things stricter instead.

Companies gambling on reversal are making a calculated bet that this time will be different, that the fifth attempt will succeed where the first four failed. Maybe they're right. But maybe is a dangerous foundation for business planning when the alternative is criminal liability for possessing controlled substances.

The most aggressive version of this gamble is what some in the industry call "full steam ahead"—continuing to produce and sell products as if nothing is changing, betting that either the law will change or enforcement will be lax enough that non-compliance won't matter. Ben Kovler, the billionaire CEO who invested $68 million in hemp-derived THC beverages, essentially articulated this approach when he told Forbes: "We're approaching it as if nothing has changed—full steam ahead." But even Kovler admits the risk: if the ban stands and enforcement happens, his business "will go up in smoke."

Even Billionaires Are Gambling – And Admitting the Risk

While the hemp industry loses battle after battle in Congress, one cannabis billionaire is doubling down with a bet that would make most business owners nervous. Ben Kovler, the 46-year-old CEO and founder of Green Thumb Industries, runs a $1.1 billion cannabis company with 105 dispensaries across 14 states. He's navigated complex state-level regulations, built a publicly traded company in an industry that remains federally illegal, and established himself as one of the most successful entrepreneurs in cannabis. And in 2024, he decided to invest more than $68 million in hemp-derived THC beverages—just months before the federal government moved to ban them.

The $68 Million Bet

Kovler's investment strategy was aggressive and deliberate. Through Rythm Inc., a publicly traded company in which Green Thumb Industries holds a controlling stake, he purchased a 49.99% ownership position for $18.2 million. Then he poured in an additional $50 million via private placement and convertible notes, giving Rythm the capital to scale operations rapidly. He licensed GTI's house of brands—Rythm, Dogwalkers, Señorita—to the company, allowing it to leverage established brand recognition in the hemp beverage market. He acquired Señorita, an existing hemp beverage company, for $19 million in stock. Total investment: more than $68 million, all committed to a market that was about to face an existential regulatory threat.

In February 2026, as reported by Forbes, Kovler announced that Chicago's United Center would begin selling hemp-derived THC beverages at concerts and other live events—the first venue of its size in the country to do so. The announcement came just three months after the ban was signed into law, two months after delay legislation failed, and one month after the FDA missed its guidance deadline. While other companies were quietly exiting the market or scrambling to assess their options, Kovler was expanding distribution to one of the most prominent venues in the country.

The Bullish Case

Kovler's confidence isn't based on wishful thinking. He's identified several trends that support his thesis that hemp-derived THC beverages represent a massive market opportunity regardless of the current regulatory headwinds. The first is the decline of alcohol consumption. In August 2025, Gallup found that only 54% of Americans drink alcohol—the lowest rate in the pollster's 90-year history. Jim Beam, the iconic bourbon brand that was once owned by Kovler's own family until the 1960s, has paused production at its main distillery in Clermont, Kentucky, due to declining demand.

The second trend is the rapid expansion of hemp THC into mainstream retail. Target is testing THC beverages in its Minnesota liquor stores, making it the first big-box retailer to enter the category. Circle K has announced plans to sell hemp-derived THC beverages in as many as 3,000 stores nationwide. The products are available at major alcohol retailers like Binny's and Woodman's, at convenience stores, and through delivery platforms like DoorDash and GoPuff.

The third trend is consumer acceptance. Kovler told Forbes that "nearly half of Americans think THC should be as socially normalized as alcohol," a shift in public opinion that creates political pressure for accommodation rather than prohibition. He argues that hemp THC beverages are reaching new consumers who would never shop at a marijuana dispensary, people who drink wine or hard seltzers and see hemp beverages as a similar social lubricant without the hangover or calories.

The fourth factor is industry alignment. Alcohol retailers, who originally lobbied for the hemp ban because they saw hemp THC as unfair competition, have now switched sides and are lobbying for delay. They've discovered that hemp beverages help offset declining alcohol sales, and they have the infrastructure—age verification systems, distribution networks, regulatory compliance experience—to sell these products responsibly.

But Even Kovler Admits the Risk

Here's the part that often gets buried in the bullish narrative, the admission that reveals the fundamental uncertainty underlying even the most confident bets. When pressed by Forbes about what happens if the ban actually takes effect, Kovler's answer was direct: "If the hemp loophole closes, current hemp products would no longer be legal, so we would not be selling products that are illegal."

Translation: if the ban stands, his $68 million bet "will go up in smoke." Forbes made this explicit in their reporting: "For now, if the federal hemp ban is not struck down before November of this year, delayed or replaced with regulations, Rythm Inc.'s business, and most of the businesses in the $28 billion hemp industry will go up in smoke."

This is the critical point that separates Kovler's situation from yours as a pet owner. Kovler can afford to lose $68 million. It would be disappointing, certainly. It would represent a failed bet and a strategic miscalculation. But it wouldn't threaten his financial security, his company's survival, or his ability to continue operating in the cannabis industry. He's gambling with money he can afford to lose, making a calculated bet that the upside if he's right justifies the downside if he's wrong.

Your dog, on the other hand, can't afford to lose access to the CBD that manages their arthritis, controls their seizures, or reduces their anxiety. Your dog doesn't have a "healthy balance sheet" to weather turbulence. Your dog doesn't have alternative revenue streams to fall back on if their CBD becomes unavailable. Your dog needs their medication to work, to be available, and to be legal—not as a probable outcome or a likely scenario, but as a certainty.

While Kovler doubles down, other major players are making different calculations. Curaleaf, a Connecticut-based cannabis company with a market presence comparable to GTI's, announced it was shuttering its hemp business ahead of the ban. The company's leadership apparently concluded that the risk of being caught with non-compliant inventory after November, combined with the costs of reformulation and the uncertainty about future regulations, made exit the rational choice. Smaller brands are discontinuing products without fanfare. Retailers are reducing hemp CBD inventory. Distributors are pulling out of the category. The industry is contracting in real time, even as advocates insist that reversal is imminent.

What's Still Pending (But Unlikely to Save the Industry)

The hemp industry points to two remaining legislative options as potential paths to reversal or delay, and advocates continue to express confidence that one or both will succeed before November. Understanding these proposals—and why they face such steep odds—helps explain why proactive planning matters more than political hope.

The HEMP Act: Regulation Instead of Prohibition

The Hemp Enforcement, Modernization, and Protection Act, introduced by Representative Morgan Griffith of Virginia (a Republican) and Representative Marc Veasey of Texas (a Democrat), represents the industry's preferred alternative to the outright ban. Rather than prohibiting hemp-derived cannabinoid products, the HEMP Act would create a comprehensive regulatory framework similar to what exists for alcohol or tobacco. The bill would establish clear rules for manufacturing, testing, labeling, and distribution, bringing hemp products out of the regulatory gray zone and into a structured compliance system.

The specifics of the HEMP Act are detailed and thoughtful. Products would be limited to adults 21 and older, with strict age verification requirements at point of sale. Packaging couldn't appeal to youth and would need to be tamper-proof, addressing one of the primary concerns that drove support for the ban. Labels would need to list all cannabinoids present and include a QR code linking to a certificate of analysis. Manufacturers would be prohibited from adding substances like alcohol, caffeine, tobacco, nicotine, or melatonin.

The bill would also establish cannabinoid limits, though more generous than the current 0.4-milligram standard. Products could contain up to five milligrams of total cannabinoids per serving and 30 milligrams per package. The HHS Secretary—currently Robert F. Kennedy Jr., who has expressed interest in alternative health approaches—would have authority to adjust these limits based on scientific evidence and public health considerations.

The HEMP Act has genuine bipartisan support, which is rare in the current political environment. Griffith and Veasey come from different parties and different regions of the country, yet they've found common ground on the principle that hemp products should be regulated rather than banned. On paper, it seems like exactly the kind of compromise that Congress should be able to pass: it addresses public health concerns through regulation while preserving a legal market and the jobs and tax revenue that come with it.

So why hasn't it passed? The answer lies in the same jurisdictional and political dynamics that have plagued every other hemp-related legislative effort. The bill needs to move through committee, get scheduled for a floor vote, pass the House, pass the Senate in identical form, and reach the President's desk for signature—all before November 12, 2026. Each of those steps requires political will, legislative time, and the absence of opposition strong enough to block progress. So far, none of those conditions have materialized.

The Hemp Planting Predictability Act: Buying Time

The alternative to creating a new regulatory framework is simply delaying the existing ban, and that's exactly what the Hemp Planting Predictability Act proposes. Introduced by Representative Jim Baird of Indiana with bipartisan support, the bill would push the implementation date back by two years, from November 2026 to November 2028. The rationale is straightforward: farmers make planting decisions months in advance based on expected market conditions, and the sudden imposition of a ban doesn't give them adequate time to adjust.

Baird's argument resonates particularly strongly in agricultural states where hemp has become an important crop. Kentucky, which championed hemp legalization in 2018 under the leadership of Senator Mitch McConnell, has seen significant investment in hemp farming infrastructure. North Carolina has developed a substantial hemp industry. Indiana has farmers who planted hemp expecting to harvest and sell it under the legal framework that existed when they made their planting decisions.

The Hemp Planting Predictability Act has attracted cosponsors from both parties and both chambers of Congress. Senators Rand Paul of Kentucky and Jeff Merkley of Oregon have introduced companion legislation in the Senate. Like the HEMP Act, it represents a reasonable compromise that addresses legitimate concerns without simply maintaining the status quo indefinitely.

But also like the HEMP Act, it hasn't passed. Baird filed an amendment to include delay language in the 2026 Farm Bill, but he was absent from the crucial markup hearing following the death of his wife, and the amendment was withdrawn. The standalone bill remains pending, but it faces the same legislative obstacles as every other hemp-related proposal.

Why These Bills Face Long Odds

The fundamental problem isn't the merits of the legislation—both the HEMP Act and the delay bill have legitimate policy rationales and bipartisan support. The problem is the political and procedural reality of getting anything passed in the current Congress. The House Agriculture Committee has made clear that finished hemp products fall outside its jurisdiction, punting responsibility to the Energy and Commerce Committee. But Energy and Commerce hasn't taken up the issue, creating a jurisdictional no-man's-land where neither committee feels ownership of the problem.

There's also the opposition to consider. Youth advocacy groups like One Chance to Grow Up have celebrated the ban as a victory for child safety, arguing that intoxicating hemp products have been too easily accessible to minors. These groups have political influence, particularly with lawmakers concerned about being seen as soft on youth substance use.

The legislative calendar creates additional pressure. Congress has a limited number of days in session between now and November, and those days are already filled with must-pass legislation like appropriations bills, debt ceiling negotiations, and other priorities that command attention. Hemp policy, despite affecting a $28 billion industry, isn't at the top of the legislative agenda.

Finally, there's the question of presidential support. President Trump signed the ban into law in November 2025, though it's unclear whether he specifically endorsed the hemp provisions or simply accepted them as part of a larger government funding package. He later issued an executive order on cannabis rescheduling that included language about protecting access to full-spectrum CBD, which hemp advocates have interpreted as a signal of openness to hemp policy reform. But executive orders don't override statutes, and Trump hasn't explicitly called for Congress to reverse or delay the hemp ban.

What Pet Owners Should Do Right Now

If you're currently using CBD for your dog, the next eight months will determine whether you have uninterrupted access to the product that helps manage their condition. The decisions you make now—which brand to trust, whether to switch proactively or wait and see, how to evaluate compliance claims—will directly affect your dog's quality of life come December.

Understand What You're Currently Using

The first step is understanding exactly what's in your current CBD product, because not all CBD is created equal and the legal distinctions matter enormously under the new law. Look at your product label and find the cannabinoid profile, which should list the amounts of CBD, CBG, CBN, and THC per serving and per container. If your product is labeled "full-spectrum," it almost certainly contains more than 0.4 milligrams of total THC per bottle, which means it will be non-compliant after November unless the company reformulates.

The best way to verify what's actually in your product is to request the Certificate of Analysis, or COA, from the manufacturer. Reputable companies conduct third-party testing on every batch and make the results publicly available, either on their website or by request. The COA will show the exact cannabinoid content measured by an independent laboratory, including total THC. If your current brand doesn't provide COAs, that's a red flag regardless of the regulatory changes.

Once you have the COA, look at the total THC content per container. If it's more than 0.4 milligrams, your product will be non-compliant after November 12, 2026. That doesn't mean it's dangerous or ineffective—it just means it won't be legal under the new definition of hemp.

Evaluate Your Brand's Compliance Plan

Not all CBD companies are responding to the regulatory changes in the same way, and understanding your brand's strategy will help you assess whether they'll still be serving customers after November. Has the company publicly acknowledged the hemp ban and its impact on their products? Have they announced a reformulation plan with a specific timeline? Are they being transparent about their current compliance status, or are they making vague claims about "monitoring the situation" without committing to concrete action?

Be skeptical of companies that claim they're "already compliant" without providing evidence. If they're selling full-spectrum products, they're almost certainly not compliant with the 0.4-milligram limit unless they've already reformulated and updated their COAs to reflect the change. Ask for documentation. Request updated test results showing 0.0% THC or total THC below 0.4 milligrams per container.

Also be wary of companies that are clearly gambling on legislative reversal without a backup plan. If their public statements focus entirely on advocacy efforts and political optimism without mentioning reformulation, they're betting that the ban will be reversed or delayed. They might be right, but if they're wrong, they'll be scrambling in October to reformulate under impossible time pressure.

Look for companies that are being proactive and transparent. Companies that have acknowledged the regulatory challenge, announced reformulation plans, provided timelines for when compliant products will be available, and committed to maintaining quality throughout the transition.

Don't Panic Buy or Stockpile

Your first instinct might be to stock up on your current CBD while it's still available, buying enough to last through the uncertainty and beyond. This is understandable but ultimately counterproductive for several reasons. First, CBD has a limited shelf life—typically six to twelve months depending on storage conditions. The cannabinoids degrade over time, particularly when exposed to light and heat, which means that product you buy today might be significantly less potent by the time you use it next year.

Second, stockpiling non-compliant products could create legal risk after November. While it's unlikely that individual pet owners will face prosecution for possessing CBD that was legal when purchased, the technical legal status of that product changes on November 12, 2026. It becomes marijuana under the Controlled Substances Act, which means possessing it is technically illegal regardless of when you bought it.

Third, stockpiling assumes that your current brand won't successfully reformulate, which may not be true. If your brand does reformulate and produce compliant products before November, you'll have wasted money buying extra inventory of the old formulation when you could have simply transitioned to the new one.

The better approach is to identify a brand that's reformulating proactively, switch to them now or in the coming months, and trust that they'll have compliant products available when you need them.

Consider Switching to a Proactive Brand Now

Why wait until your current brand scrambles in October when you can switch to a brand that's planning ahead? The advantages of switching now, rather than waiting to see what happens, are substantial. First, you avoid the supply disruptions that will likely occur in the fall as companies rush to reformulate and retailers adjust their inventory. Second, you give your dog time to adjust to a new product gradually rather than being forced to switch abruptly when your current brand becomes unavailable. Third, you support companies that are doing the right thing—being transparent, planning proactively, and prioritizing customer access over political gambling.

When evaluating potential brands to switch to, look for several key indicators of quality and reliability. Third-party testing on every batch is non-negotiable—you should be able to access COAs that show exactly what's in the product you're buying. Transparency about reformulation plans matters—the company should be clear about their current status and their timeline for achieving compliance. A track record of quality and consistency is important—look for companies that have been in business for a while and have established reputations rather than newcomers trying to capitalize on the regulatory chaos.

Also consider the company's formulation philosophy. Are they committed to preserving the beneficial cannabinoids and terpenes even while removing THC, or are they simply creating a CBD isolate product that meets the legal standard but loses the potential benefits of the entourage effect? Though it's not solventless, we're experts in THC-removal processes that achieve 0.0% THC while preserving CBD, CBG, CBN, and the full terpene profile—maintaining a broad-spectrum formulation that offers the potential benefits of multiple cannabinoids working together, just without the THC that creates regulatory risk.

Talk to Your Veterinarian

If your dog is on CBD for a specific medical condition—arthritis, seizures, anxiety, inflammatory bowel disease—discuss the upcoming regulatory changes with your veterinarian. They need to know that the product your dog has been taking might become unavailable or might change formulation, because that could affect treatment planning. Ask whether the reformulated version is likely to work as well as the current formulation. Discuss whether you should adjust dosing during the transition. Talk about alternative therapies to consider if CBD becomes unavailable or if the reformulated product doesn't work as well.

Your veterinarian can also help you monitor your dog's response to any formula changes. If you switch brands or if your current brand reformulates, watch for changes in your dog's symptoms, behavior, or overall condition. Some dogs might respond just as well to a broad-spectrum formulation with 0.0% THC as they did to a full-spectrum product with trace THC. Others might show some difference in response, requiring dosage adjustments or additional supportive care.

Stay Informed About State-Level Developments

Don't assume you have until November 12, 2026, to make decisions. Some states are acting sooner, imposing their own restrictions on hemp-derived products ahead of the federal deadline. Ohio has already banned intoxicating hemp products as of December 2025. New Jersey has advanced legislation requiring accelerated liquidation of non-compliant inventory. Other states are considering similar measures.

Check your state's hemp and cannabis regulatory agency websites for updates on state-level action. Sign up for email alerts from industry groups like the U.S. Hemp Roundtable, which tracks state legislative developments. And if you travel with your dog across state lines, be aware that hemp products legal in your home state might be illegal in states you're visiting.

Frequently Asked Questions

Will all CBD be illegal after November 2026?

No, CBD itself is not being banned. What's changing is the definition of legal hemp and the THC limits for finished products. The confusion is understandable because the media coverage often uses shorthand like "hemp ban" that makes it sound like all hemp-derived products will become illegal. But the reality is more nuanced. The law targets products based on their total THC content, not their CBD content. Products that contain CBD but meet the new THC limits will remain perfectly legal. Specifically, products with 0.0% THC (true broad-spectrum formulations or isolates) and products containing only naturally occurring, non-THC cannabinoids like CBD, CBG, and CBN will remain legal. The challenge is that most current pet CBD products are full-spectrum formulations with trace amounts of THC that exceed the new limit.

Why is the industry so confident after losing every battle?

The industry's continued optimism is based on several factors that, while not unreasonable, haven't yet translated into actual victories. First, there's the economic impact argument. A $28.4 billion industry supporting 300,000 jobs and generating $1.5 billion in state tax revenue represents significant economic activity that Congress typically tries to protect rather than eliminate. Second, there's the shift in the alcohol industry's position. Retailers who originally lobbied for the hemp ban have now switched sides and are lobbying for delay, creating political leverage that didn't exist when the ban was first proposed. Third, there's genuine bipartisan support for alternative approaches like the HEMP Act and delay bills. Fourth, there's President Trump's executive order on cannabis rescheduling and CBD access, which hemp advocates interpret as a signal of openness to hemp policy reform. Finally, there's simple momentum and sunk costs—companies have invested billions in this industry over eight years, and walking away from all that investment is psychologically difficult. But optimism based on reasonable assumptions isn't the same as results based on legislative action.

Should I trust the industry's "winnable fight" claim?

That's ultimately a decision you need to make based on your own assessment of the evidence and your tolerance for risk. The case for trusting the industry's optimism rests on the economic impact, political support, and industry alignment mentioned above. The case for skepticism rests on the track record: four attempts, four failures, eight months remaining, and no indication that the political dynamics have fundamentally changed. Here's how to think about it: if you're making a decision that affects only you, and if you can afford to be wrong, then betting on the industry's optimism might be reasonable. But if you're making a decision that affects your dog's health, and if being wrong means your dog loses access to medication that manages their chronic condition, then the calculation changes. The question isn't whether reversal is possible—it clearly is. The question is whether it's probable enough to justify the risk of being wrong.

What's the difference between full-spectrum and broad-spectrum CBD?

The distinction between full-spectrum and broad-spectrum CBD is chemical, not just marketing terminology, and it has significant implications for both therapeutic effects and legal compliance. Full-spectrum CBD contains all the naturally occurring compounds from the hemp plant, including CBD, CBG, CBN, trace amounts of THC in various forms, and the full complement of terpenes and flavonoids. Broad-spectrum CBD, by contrast, contains all of those compounds except THC. The THC is removed through post-processing techniques like chromatography, which selectively separates THC molecules from the other cannabinoids. The goal is to preserve the potential benefits of the entourage effect while eliminating the compound that creates regulatory risk. A true broad-spectrum product should show 0.0% THC on third-party testing. There's also CBD isolate, which is pure CBD with all other compounds removed. Isolate is the simplest path to compliance because it contains no THC by definition, but it loses any potential benefits from the entourage effect. For pet owners, the practical question is whether a broad-spectrum product will work as well as the full-spectrum product their dog has been taking. The honest answer is that we don't know for certain, but the trace amounts of THC in full-spectrum pet CBD products are so small that their direct contribution to therapeutic effects is probably minimal.

Are states acting before the November federal deadline?

Yes, and this is one of the most underreported aspects of the regulatory changes. While the federal ban doesn't take effect until November 12, 2026, several states are not waiting for that deadline. Ohio enacted Senate Bill 56 in December 2025, imposing a categorical ban on intoxicating hemp products that took effect immediately. New Jersey has advanced legislation requiring the liquidation of non-compliant inventory on an accelerated timeline. Other states are considering similar measures. States have their own regulatory authority over products sold within their borders, and they're not obligated to wait for federal action before imposing their own restrictions. For businesses operating nationally, this creates a compliance nightmare—a product legal in one state might already be illegal in another. For pet owners, the practical implication is that you can't assume you have until November to make decisions. Check your state's hemp and cannabis regulatory agencies for updates on state-level action.

Is VetsGrade currently compliant with the new law?

No, not yet, and transparency about this matters more than false reassurance. Our current products use full-spectrum, solventless extraction that preserves all the naturally occurring compounds from the hemp plant, including trace amounts of THC. When measured per bottle, our products likely contain more than 0.4 milligrams of total THC, which means they would be non-compliant under the new definition that takes effect in November. But here's what makes VetsGrade different: rather than hiding this reality or gambling on the law changing, reformulation is underway now to achieve true 0.0% THC while preserving CBD, CBG, CBN, and the full terpene profile. The timeline targets Q3 2026 completion, well before the November deadline. When the reformulated products launch, they'll meet the same quality standards customers expect, they'll be thoroughly tested and documented with updated COAs, and they'll be compliant well before the deadline. Transparency about current status, combined with proactive planning for future compliance, builds trust more effectively than false claims of being ready when the reality is otherwise.

Will reformulated CBD work as well as full-spectrum?

This is the question that concerns pet owners most, and it deserves an honest, nuanced answer rather than simple reassurance. The theory behind full-spectrum CBD is the entourage effect—the idea that cannabinoids work better together than in isolation. Proponents argue that removing THC diminishes the product's effectiveness, even if only marginally. The counterargument is that the trace amounts of THC in full-spectrum pet CBD products—typically two to ten milligrams per bottle in formulations containing 500 milligrams of CBD—are so small that their direct contribution to therapeutic effects is minimal. The ratio is heavily weighted toward CBD, often 50:1 or 100:1, which suggests that the vast majority of therapeutic benefit comes from the CBD itself. The real entourage effect, according to this view, comes from the interaction of CBD with CBG, CBN, and terpenes—all of which can be preserved in a broad-spectrum formulation even after THC is removed. The scientific evidence on this question is mixed and incomplete. Most of the 223 peer-reviewed studies that inform VetsGrade's approach to CBD for dogs used CBD-dominant formulations, not necessarily full-spectrum products with specific THC ratios. What we can say is that any difference is likely to be small given the low THC levels involved, and that proper dosing and product quality probably matter more than the presence or absence of trace THC. VetsGrade's commitment is to maintain quality throughout the reformulation process, creating a true broad-spectrum formulation that preserves CBD, CBG, CBN, and the full terpene profile while removing only the THC that creates regulatory risk.

When should I switch to a compliant brand?

The decision of when to switch depends on your current brand's status and your tolerance for uncertainty. If your current brand hasn't announced a reformulation plan, hasn't been transparent about their compliance status, or is clearly gambling on legislative reversal without a backup plan, you should consider switching now rather than waiting. The risk of waiting is that you'll be forced to switch abruptly in October or November when your brand either exits the market or rushes out a reformulated product that hasn't been properly tested. Switching now gives you and your dog time to adjust gradually, ensures continuity of supply, and supports companies that are doing the responsible thing. If your current brand has announced a clear reformulation plan with a specific timeline, has been transparent about their current status and future plans, and has a track record of quality and reliability, you might choose to wait and transition when they launch their reformulated product. But even in that scenario, there's value in having a backup plan. What if the reformulation takes longer than expected? What if the reformulated product doesn't work as well for your dog? Having identified an alternative brand that's already reformulating gives you options if your primary choice doesn't work out as planned.

What if the ban is reversed or delayed?

If the ban is reversed or significantly delayed before November, the industry will celebrate and companies will reassess their reformulation timelines accordingly. One possibility is that brands might offer both full-spectrum and broad-spectrum options if the regulatory environment allows for it. Some customers might prefer the original full-spectrum formulation if it remains legal, while others might prefer the certainty of a 0.0% THC broad-spectrum product that faces no regulatory risk regardless of future policy changes. Another possibility is that companies complete the reformulation anyway, even if the ban is reversed, because a 0.0% THC broad-spectrum product has advantages beyond regulatory compliance. It eliminates any concern about drug testing for pet owners who are subject to workplace testing. It removes any ambiguity about psychoactive effects. It future-proofs against potential regulatory changes down the road. The key point is this: planning for the ban to take effect as scheduled, and ensuring compliance regardless of what happens politically, means your dog has certainty. If the ban is reversed, that's wonderful—compliant products will exist in a legal market with more options than expected. If the ban takes effect, compliant products will exist in a restricted market where many competitors have failed to prepare. Either way, your dog has access to quality CBD.

In Conclusion: Choose Certainty Over Gambling

Eight months remain until the ban takes effect. The path forward is clear for pet owners who want to ensure their dog has uninterrupted access to quality CBD: choose brands that are reformulating proactively rather than gambling on political outcomes that haven't materialized despite months of advocacy.

The Choice Is Yours

You can gamble with the industry, hoping that the ban will be reversed or delayed, trusting that your current brand will successfully reformulate in time despite waiting until the last minute, accepting the risk of supply disruptions and quality issues that come with rushed compliance efforts. This approach might work out. The industry might win its next legislative battle. Your brand might execute a flawless reformulation in the limited time remaining. Political winds might shift and create the legislative opening that hasn't appeared yet. It's possible.

Or you can choose certainty, switching to a brand that's planning ahead rather than gambling on political outcomes, supporting transparency over false reassurance, ensuring your dog has uninterrupted access to quality CBD regardless of what happens in Washington. This approach guarantees that your dog's medication will be available, legal, and effective come December, whether the ban takes effect as scheduled or gets reversed at the last minute.

The difference between these approaches is the difference between hope and planning, between gambling and certainty, between reactive scrambling and proactive preparation. Both might lead to the same outcome if the industry's optimism proves justified. But if that optimism proves misplaced—if November arrives and the ban takes effect and companies that waited are scrambling or exiting—only one approach ensures your dog doesn't suffer the consequences of someone else's miscalculation.

Your Dog Can't Wait for Political Miracles

If your dog has arthritis, they need pain relief today, not after Congress maybe passes a bill that might delay implementation. The inflammation in their joints doesn't pause while advocates lobby for regulatory accommodation. If your dog has seizures, they need consistent access to the CBD that helps control their condition, not supply disruptions caused by manufacturers scrambling to reformulate in October. Seizure management requires consistency—consistent dosing, consistent product quality, consistent availability. If your dog has anxiety that makes thunderstorms or fireworks unbearable, they need a product you can count on being available when you need it, not a product that might disappear from shelves because the company gambled on legislative reversal and lost.

Last updated: March 10, 2026 | Have questions about the 2026 hemp ban or reformulation plans? Contact our team | Read our comprehensive CBD guide based on 223+ peer-reviewed studies

---

Related Resources

→ CBD for Dogs: Complete Evidence-Based Guide (223+ Studies)
→ CBD Dosing Calculator for Dogs
→ Third-Party Testing & Certificates of Analysis
→ Relief+ CBD Tincture for Dogs
→ Contact VetsGrade